Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Sera Prognostics, Inc.NASDAQ: SERA

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital growth accelerates

Q1 FY2026 change in working capital of $1.46M (cash outflow) rose 18.3% year over year, ahead of the -39.5% change in trailing-twelve-month change in working capital.

Context

  • Change in working capital amounted to 674.1% of revenue in FY2025, down 13968.8 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.3% holds above the trailing-twelve-month pace of -39.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.46M-868.4% QoQ
Last fiscal yearDec 2025
-$546K-104.8% YoY
LTMMar 2026
-$772K-39.5% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.3%——
1 year-104.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(546K) USD
Year-over-year change
-104.8%

Change in Working Capital vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -39.5% is the 5th highest of 8, against a peer median of +28.5%.
  • Change in working capital amounts to 1354.4% of revenue for SERA, versus a peer median of 14.0%.
SERA Competitors
Change in Working Capital for SERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STSSSkyAI, Inc.LTM Mar 2026$6.21M USD+1044.6%—1565.6%
APYXApyx Medical CorporationLTM Mar 2026$3.4M USD-235.0%-32.7%6.1%
HURATuHURA Biosciences, Inc.LTM Mar 2026$3.33M USD———
LUCDLucid Diagnostics Inc.LTM Mar 2026$3.16M USD+28.5%—61.5%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$3.13M USD+392.8%—9.1%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$2.8M USD+129.3%+54.2%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$1.46M CAD-46.2%+60.6%—
SRZNSurrozen, Inc.LTM Mar 2026$1.05M USD-109.9%—14.0%
SERASera Prognostics, Inc.LTM Mar 2026$772K USD-39.5%—1354.4%
Peer median (excluding SERA) —+28.5%+54.2%14.0%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Depreciation & Amortization659K756K900K833K940K
Deferred Income Tax00000
Stock-Based Compensation3.13M5.06M5.27M7.01M5.11M
Change in Working Capital(44K)3.55M3.52M11.28M(546K)
Accounts Receivables(3.14M)(2.97M)(5.36M)11.42M22K
Inventory00000
Accounts Payables603K352K(442K)455K(1.01M)
Other Working Capital2.49M6.17M9.32M(597K)441K
Other Non-Cash Items(372K)213K(638K)(412K)801K
Operating Cash Flow(31.64M)(34.61M)(27.19M)(14.19M)(25.62M)
Capital Expenditures(1.3M)(791K)(128K)(1.1M)(726K)
Acquisitions (Net)00000
Purchases of Investments(82.06M)(48.07M)(54.14M)(35.83M)(87.61M)
Sales of Investments800K54.4M54.4M48.68M59.84M
Other Investing Activities016K311K(1.05M)0
Investing Cash Flow(82.56M)5.55M438K11.74M(28.5M)
Debt Repayment(7.66M)(303K)(466K)(440K)(194K)
Common Stock Issued66.61M00054.22M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.66M308K1.22M3.05M0
Financing Cash Flow159.59M5K752K2.61M54.03M
Effect of Forex Changes00000
Net Change in Cash45.4M(29.05M)(26M)163K(99K)
Free Cash Flow(32.94M)(35.4M)(27.32M)(15.29M)(26.35M)

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.